Retatrutide (also known as LY-3437943) is an experimental medication developed by Eli Lilly that is being studied as a next-generation treatment for obesity, overweight, and related metabolic conditions such as type 2 diabetes
Samples were run on either a SeQuant ZIC-pHILIC LC column, 5 m, 150 4.6 mm (MilliporeSigma, Burlington, MA) with a SeQuant ZIC-pHILIC guard column, 20 4.6 mm (MilliporeSigma, Burlington, MA) or an Atlantis Premier BEH Z-HILIC VanGuard FIT column, 2.5 m, 2.1 mm 150 mm (Waters, Milford, MA)
Novo Nordisks semaglutide, for example, has demonstrated powerful market dominance due to its additional cardiovascular benefits
KLOW is the quad-peptide version, adding KPV to the triple-peptide GLOW blend (GHK-Cu, BPC-157, TB-500)
Safety and precautions: Because pure bacteriostatic water is hypotonic, it should not be injected alone intravenously (doing so can cause red cell hemolysis)